Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019;17:181–92 https://www.nature.com/articles/s41579-018-0118-9

Severe Acute Respiratory Syndrome Coronavirus as an Agent of Emerging and Reemerging Infection. Clin Microb Rev, (2007), p. 660–694 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2176051/

Bats as reservoirs of severe emerging infectious diseases. Virus Research 205 (2015) 1–6 <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132474/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132474/</a>

Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. Current biology : CB vol. 30,7 (2020): 1346-1351.e2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156161/

Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med (2020). https://www.nature.com/articles/s41591-020-0897-1

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends in Immunology Vol. 41, Issue 5, May 2020, p. 355-359 https://www.sciencedirect.com/science/article/pii/S1471490620300570

Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019; 17(3): 181–192. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097006/

Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. https://www.biorxiv.org/content/10.1101/2020.03.13.990226v2

Potent human neutralizing antibodies elicited by SARS-CoV-2. https://www.biorxiv.org/content/10.1101/2020.03.21.990770v2

Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus. Science 01 May 2020: Vol. 368, Issue 6490, pp. 489-493 <u>https://science.sciencemag.org/content/368/6490/489</u>

Evaluations of serological test in the diagnosis of 2019 2 novel coronavirus (SARS-CoV-2) infections.

https://www.medrxiv.org/content/10.1101/2020.03.27.20045153v1

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) [published online ahead of print, 2020 Mar 21]. Clin Infect Dis. 2020;ciaa310. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184472/

A serological assay to detect SARS-CoV-2 seroconversion in humans. https://www.medrxiv.org/content/10.1101/2020.03.17.20037713v2

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. [published online ahead of print, 2020 Mar 28]. Clin Infect Dis. 2020;ciaa344. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184337/ Evaluation of nine commercial SARS-CoV-2 immunoassays. https://www.medrxiv.org/content/10.1101/2020.04.09.20056325v1

Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset. <u>https://www.medrxiv.org/content/10.1101/2020.03.23.20041707v1</u>

NUOVI Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020 May 6. doi: 10.1001/jama.2020.8259. [Epub ahead of print] <u>https://jamanetwork.com/journals/jama/fullarticle/2765837</u>

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction <u>https://www.nature.com/articles/s41587-020-0631-z</u>